Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

Increased mTOR activation in idiopathic multicentric Castleman disease

(2020) Daniel J. Arenas et al.   BLOOD

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

(2019) David C. Fajgenbaum et al.   JOURNAL OF CLINICAL INVESTIGATION

Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease

(2018) Sheila K. Pierson et al.   AMERICAN JOURNAL OF HEMATOLOGY

Acute Loss of Apolipoprotein E Triggers an Autoimmune Response That Accelerates Atherosclerosis

(2018) Monica Centa et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin

(2018) Yusuke Takayama et al.   INTERNAL MEDICINE

Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease

(2018) Hiroaki Nishioka et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Successful treatment with tacrolimus in TAFRO syndrome

(2018) Taiichiro Shirai et al.   MEDICINE

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

(2018) Frits van Rhee et al.   BLOOD

Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells

(2018) Mulugeta M. Zegeye et al.   Cell Communication and Signaling

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

(2018) David C. Fajgenbaum   BLOOD

Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan

(2017) Shino Fujimoto et al.   Modern Rheumatology

Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome

(2016) Yusuke Yamaga et al.   INTERNAL MEDICINE

Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease

(2016) Peter Ganz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A case of TAFRO syndrome, a variant of multicentric Castleman’s disease, successfully treated with corticosteroid and cyclosporine A

(2016) Naruhiko Takasawa et al.   Modern Rheumatology

Idiopathic multicentric Castleman's disease: a systematic literature review

(2016) Amy Y Liu et al.   Lancet Haematology

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

(2015) C. Casper et al.   CLINICAL CANCER RESEARCH

Emerging Functions of Amphiregulin in Orchestrating Immunity, Inflammation, and Tissue Repair

(2015) Dietmar M.W. Zaiss et al.   IMMUNITY

Clinical and morphological features of different types of Castleman’s disease

(2015) A. L. Melikyan et al.   TERAPEVTICHESKII ARKHIV

Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman’s Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2

(2015) Yoshinobu Konishi et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

(2014) Nikhil Munshi et al.   LEUKEMIA & LYMPHOMA

A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma

(2014) Claudia Döring et al.   MODERN PATHOLOGY

The clinical spectrum of Castleman's disease

(2012) Angela Dispenzieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery

(2011) Larry Gold et al.   PLoS One

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)

(2010) H. El-Osta et al.   MOLECULAR CANCER THERAPEUTICS